Abivax SA (France) Performance
| ABVX Stock | EUR 7.95 0.26 3.38% |
The firm shows a Beta (market volatility) of 0.0923, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Abivax SA's returns are expected to increase less than the market. However, during the bear market, the loss of holding Abivax SA is expected to be smaller as well. At this point, Abivax SA has a negative expected return of -0.55%. Please make sure to confirm Abivax SA's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if Abivax SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Abivax SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 29.3 M | |
| Total Cashflows From Investing Activities | -1.5 M |
Abivax |
Abivax SA Relative Risk vs. Return Landscape
If you would invest 1,170 in Abivax SA on September 2, 2024 and sell it today you would lose (375.00) from holding Abivax SA or give up 32.05% of portfolio value over 90 days. Abivax SA is generating negative expected returns and assumes 2.6203% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Abivax, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Abivax SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abivax SA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abivax SA, and traders can use it to determine the average amount a Abivax SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2098
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABVX |
Estimated Market Risk
| 2.62 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.55 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Abivax SA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abivax SA by adding Abivax SA to a well-diversified portfolio.
Abivax SA Fundamentals Growth
Abivax Stock prices reflect investors' perceptions of the future prospects and financial health of Abivax SA, and Abivax SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abivax Stock performance.
| Return On Equity | -12.86 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | 4.66 % | |||
| Current Valuation | 157.22 M | |||
| Shares Outstanding | 42.32 M | |||
| Price To Earning | (7.59) X | |||
| Price To Book | 22.19 X | |||
| Price To Sales | 3,840 X | |||
| Revenue | 37 K | |||
| EBITDA | (42.25 M) | |||
| Cash And Equivalents | 6 K | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 53.45 M | |||
| Debt To Equity | 31.40 % | |||
| Book Value Per Share | 0.36 X | |||
| Cash Flow From Operations | (45.66 M) | |||
| Earnings Per Share | (2.37) X | |||
| Total Asset | 110.36 M | |||
| Retained Earnings | (29 M) | |||
| Current Asset | 34 M | |||
| Current Liabilities | 4 M | |||
About Abivax SA Performance
By analyzing Abivax SA's fundamental ratios, stakeholders can gain valuable insights into Abivax SA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Abivax SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Abivax SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ABIVAX Socit Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. The company was incorporated in 2013 and is headquartered in Paris, France. ABIVAX is traded on Paris Stock Exchange in France.Things to note about Abivax SA performance evaluation
Checking the ongoing alerts about Abivax SA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abivax SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abivax SA generated a negative expected return over the last 90 days | |
| The company reported the revenue of 37 K. Net Loss for the year was (41.36 M) with loss before overhead, payroll, taxes, and interest of (45.52 M). | |
| Abivax SA has accumulated about 6 K in cash with (45.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. |
- Analyzing Abivax SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abivax SA's stock is overvalued or undervalued compared to its peers.
- Examining Abivax SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abivax SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abivax SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abivax SA's stock. These opinions can provide insight into Abivax SA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Abivax Stock analysis
When running Abivax SA's price analysis, check to measure Abivax SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abivax SA is operating at the current time. Most of Abivax SA's value examination focuses on studying past and present price action to predict the probability of Abivax SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abivax SA's price. Additionally, you may evaluate how the addition of Abivax SA to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |